A summary of the selected distribution of genes of interest according to the Gene Ontology Classification of Biological Processes is shown inFig. microarray technology. Furthermore, the intracellular production of crucial neuro-regenerative NTs (i.e., BDNF and NT-3) was assessed in NCs and lineage-negative cells after incubation for 24, 48, and 72 h in both serum and (S)-2-Hydroxy-3-phenylpropanoic acid serum-free conditions. We discovered significantly higher expression of NTs and NT receptors at both the mRNA and protein level in lineage-negative, CD34+, and CD133+cells than in NCs. Global gene expression analysis revealed considerably higher expression of genes associated with the production and secretion of proteins, migration, proliferation, and differentiation in lineage-negative cells than in CD34+or CD133+cell populations. Notably, after short-term incubation under serum-free conditions, lineage-negative cells and NCs produced significantly higher amounts of BDNF and NT-3 than under steady-state conditions. Finally, conditioned medium (CM) from lineage-negative SPCs exerted a beneficial impact on neural cell survival and proliferation. == Conclusions == Collectively, our findings demonstrate that UCB-derived SPCs highly express NTs and their relevant receptors under steady-state conditions, NT expression is greater under stress-related conditions and that CM from SPCs favorable influence neural Rabbit polyclonal to Dopey 2 cell proliferation and survival. Understanding the mechanisms governing the characterization and humoral activity of subsets of SPCs may yield (S)-2-Hydroxy-3-phenylpropanoic acid new therapeutic strategies that might be more effective in treating neurodegenerative disorders. == Introduction == Neurodegenerative diseases (NDs), such as amyotrophic lateral sclerosis, Alzheimer’s disease, Huntington’s disease, age-related macular degeneration, and Parkinson’s disease are characterized clinically by their subtle onset but chronic progression and involve the degeneration of defined neuronal phenotypes in the central nervous system (CNS). Despite substantial research and the development of a number of neuroprotective drugs to treat NDs and to improve patient survival, no effective therapy for these diseases is currently available. Recently, stem cell-based therapy has been considered a novel therapeutic strategy for this group of disorders. Populations of stem cells from a variety of sources have been implicated in the regeneration of damaged neural cells. Human umbilical cord blood (UCB) is an attractive source of transplantable cells for use in regenerative medicine. As widely disseminated in the literature, human UCB is enriched in stem/progenitor cells (SPCs) that are able to give rise to multiple neural lineage cell types[1],[2]. In addition to findings from numerous in vitro experiments[3][6], several in vivo findings have provided data on the ameliorative effects of UCB-derived cells when transplanted into animal models of neurodegenerative diseases[7][9]. Therapeutic approaches involving the transplantation of stem cells focuses primarily on the replacement of lost neurons and the restoration of neural tissue structure. Although these experimental studies demonstrate that UCB-derived cells are capable of surviving transplantation, convincing evidence that they are able to differentiate into mature neurons is lacking. The reported beneficial effects of stem cell-based therapy may depend on the trophic activity of producing various cytokines, including neurotrophins (NTs), which regulate the growth, differentiation, and migration of neural SPCs. In recent years, numerous studies have shown that stem cell transplantation elicits neurogenesis and angiogenesis by releasing neuroprotective factors (e.g., brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF))[10]. Despite the efforts made and the encouraging results reported, unresolved questions remain regarding the optimal population of stem cells that should be used to provide the best outcome in in vivo transplantation[11],[12]. The characterization of SPC subsets and an assessment of their ability to produce various NTs in vitro may stimulate the field of regenerative medicine by offering novel targets. In this context, identification of the optimal SPC population for neural tissue repair is paramount to the differentiation of transplanted stem cells. Insights into NT production by stem cells may help in devising more effective therapies and introduce widely extendable (S)-2-Hydroxy-3-phenylpropanoic acid clinical applications. Growing evidence suggests that UCB cell-induced neuroprotection involves anti-inflammatory and immunomodulatory effects, and that neurotrophic factors act through paracrine and/or autocrine interactions between transplanted UCB-derived cells and the neural microenvironment[13][15]. NTs regulate the growth, differentiation, and migration of neural cells and have been proposed to act as therapeutic agents for the treatment of neurodegenerative disorders[16]. However, NTs generally do not cross the blood-brain barrier (S)-2-Hydroxy-3-phenylpropanoic acid to any substantial degree, and direct injection into neural tissue to target the effects of.